1.
Harrington P, Dillon R, Radia D, Rousselot P, McLornan DP, Ong M, Green A, Verde A, Hussain F, Raj K, Kordasti S, Harrison C, de Lavallade H. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia. haematol [Internet]. 2023Jun.1 [cited 2024May25];108(6):1555-66. Available from: https://haematologica.org/article/view/haematol.2022.282005